ArticleMolecular therapy. Oncology2025

Preclinical study of inetetamab combined with atezolizumab to synergistically inhibit HER2 and PD-L1 in the treatment of ovarian cancer.

Feiquan Ying et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.